Canaccord Genuity maintains Ultragenyx Pharmaceutical at Buy, lowers price target to $34 from $39

Canaccord Genuity maintained its Buy rating on Ultragenyx Pharmaceutical but lowered its price target to $34 from $39. The new target suggests a 98.1% upside from the Nov 4 close of $17.16. Recent analyst price targets for the company range from $17 to $22.

Original reporting
Published Nov 4, 2026, 11:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Canaccord Genuity maintains Ultragenyx Pharmaceutical at Buy, lowers price target to $34 from $39 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The downgrade reflects concerns about growth prospects and may trigger short‑term selling.

02

Market read

A modest analyst downgrade with limited immediate market impact.

03

What to watch

Potential upcoming clinical trial data could offset the downgrade.

Relevance 5/10Novelty 4/10Timing: post-market today

Background

Ultragenyx is a rare‑disease biotech; analyst price‑target changes are common but can move the stock.

Market effects

Minor impact on biotech sector sentiment.

Limited to US biotech investors.

Low global relevance.

Counterpoint

The target cut may be overly cautious given recent pipeline progress.

Key entities

  • Canaccord Genuity

    Provided the revised price target.

  • Ultragenyx Pharmaceutical

    Subject of the analyst downgrade.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.